Date: 2017-09-20
Type of information: Research agreement
Compound: muscle-selective promoter candidates
Company: Synpromics (UK) Solid Biosciences (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases - Neuromuscular diseases
Type agreement: research - R&D
Action mechanism: gene therapy - oligonucleotide
Disease: Duchenne muscular dystrophy (DMD)
Details:
- • On September 20, 2017, Synpromics, a leader in gene control, announced a new research partnership with Solid Biosciences. Under the terms of the agreement, Synpromics will provide Solid Biosciences access to a set of key muscle-selective promoter candidates to be used in the development of new treatment options for Duchenne muscular dystrophy.
- The use of Synpromics’ synthetic promoters will enable the enhancement of Solid Biosciences’ investigational gene therapy candidates for the treatment of DMD. These muscle-selective promoters have been designed using Synpromics’ PromPT® technology and bioinformatics expertise, and will be evaluated by Solid Biosciences for optimal product specific gene control.
- This research collaboration will help advance Solid’s programme to develop optimal product candidates for the company’s AAV muscle-directed gene therapy research programme.
Financial terms:
Latest news:
Is general: Yes
